Our therapeutic innovations are empowering people to live life – fully human.
MannKind Corporation is focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease.
Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
press releasesview all news
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetesread more
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023read more
When was MannKind Corporation founded?
What is your fiscal year?
On which exchange does MannKind trade and what is the symbol?
How do I contact your Investor Relations?
Please email firstname.lastname@example.org
Where is MannKind located?1 Casper StreetDanbury, CT 0681030930 Russell Ranch Road, Suite 300Westlake Village, CA 91362293 Boston Post Road West #330Marlborough, MA 01752
Who is your transfer agent?
P.O. Box 43006
Providence RI 02940-3006
150 Royal St., Suite 101
Canton, MA 02021
You may automatically receive MannKind Corporation information by email. Please enter your email address and provide your email preference selections. Confirm you are not a robot and click submit.